Recent advances in CAR T-cell therapy for lymphoma in China
Open accessAbstract
Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy, radiotherapy, and other advanced therapeutics, including rituximab or immune checkpoint inhibitors, have improved the prognosis in recent decades, there are still a number of patients with relapsed or refractory (R/R) lymphoma with a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy has provided a curative option for patients with relapsed or refractory lymphoma. Numerous clinical trials have been conducted worldwide and presented inspiring results that give insight into this breakthrough therapy. The development of cancer cell therapy in China has been rapid in the past years and dominates the field with the USA. This review aims to summarize the published results of CAR T-cell therapy alone or in combination with other therapies in mainland China, both in R/R NHL and R/R HL.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CAR-T-cell therapy offers durable remission and markedly extends survival in patients with relapsed/refractory large B-cell lymphoma.
“Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a revolutionary treatment; specifically, it offers durable remission and markedly extends survival in patients with relapsed/refractory large B-cell lymphoma patients.”
From The burdens, coping strategies, and unmet needs of family caregivers of Chinese patients with lymphoma receiving commercial CAR-T-cell therapy: A qualitative study (2026) · cites this paper as [6]
The Introduction (page unavailable) says CAR T-cell therapies significantly improved survival in patients with relapsed/refractory lymphoma, and the Conclusions report durable remissions in a substantial proportion of patients with relapsed/refractory lymphomas. The paper discusses large B-cell lymphoma, but these broad statements do not establish durable remission and markedly extended survival specifically for that subgroup. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · see citing works
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · see citing works
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · see citing works
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S., Svoboda, J., Chong, E., Nasta, S., Mato, A., Anak, Ö., Brogdon, J., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,599 · see citing works
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595 · cited 1× · see citing works
“AntiCD19 CAR T-cell therapies have shown high responses in R/R B-cell lymphoma [15, 16].”
BackgroundThe basic principles of chimeric antigen receptor (CAR) design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,423 · cited 1× · see citing works
“When encountered with tumors, they can rapidly generate specific tumor-targeted T cells, which may exert both immediate and long-term effects [7, 9, 10].”
BackgroundB lymphocytes: how they develop and function
LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400 · cited 1× · see citing works
“CD19 CAR T‐cell therapy CD19 is expressed by essentially all B-lineage cells and regulates the intracellular signal transduction [14].”
BackgroundFry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,336 · see citing works
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,201 · see citing works
Cancer incidence and mortality
Agovino, P. K., & Hill, S. (2019) · Health at a Glance: Europe · doi:10.4324/9780429049187-2 · Cited by 1,179 · cited 8×
“In China, the dramatic development of these gene-engineered T-cell therapies also significantly improved the survival and quality of life in patients with R/R lymphoma, especially R/R NHL.”
BackgroundInfluentialSchwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H., Schaadt, M., & Diehl, V. (1982) · Nature · doi:10.1038/299065a0 · Cited by 901
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d'Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 743 · see citing works
Attributable causes of lung cancer incidence and mortality in China
Wang, J.-B., Fan, Y.-G., Jiang, Y., Li, P., Xiao, H.-J., Chen, W.-Q., Wei, W.-Q., Zhou, Q.-H., Qiao, Y., & Boffetta, P. (2011) · Thoracic Cancer · doi:10.1111/j.1759-7714.2011.00067.x · Cited by 547
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc971 · Cited by 533 · cited 1× · see citing works
“When encountered with tumors, they can rapidly generate specific tumor-targeted T cells, which may exert both immediate and long-term effects [7, 9, 10].”
BackgroundHodgkin Lymphoma: a review and update on recent progress
Shanbhag, S., & Ambinder, R. (2017) · Ca · doi:10.3322/caac.21438 · Cited by 471 · see citing works
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J., & Rosenberg, S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 467 · see citing works
A safe and potent anti-CD19 CAR T cell therapy
Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0421-7 · Cited by 441 · see citing works
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani, S., Zinzani, P., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A., Specchia, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100340 · Cited by 418 · cited 1×
“In addition, a number of patients relapse or are refractory to the chemotherapy and/or radiotherapy, though most patients with classical HL are cured by initial therapy [4, 5].”
BackgroundCancer incidence and mortality in China, 2013.
Chen, W.-Q., Zheng, R.-S., Zhang, S.-W., Zeng, H., Xia, C., Zuo, T.-T., Yang, Z.-X., Zou, X., & He, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.024 · Cited by 403 · see citing works
CD30: expression and function in health and disease.
Horie, R., & Watanabe, T. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0156 · Cited by 338 · see citing works
Wang, C., Wu, Z., Wang, Y., Guo, Y., Dai, H., Wang, X., Li, X., Zhang, Y.-J., Zhang, W., Chen, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 332 · see citing works
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Yang, J. C.-H., Sherry, R. M., Feldman, S. A., McIntyre, L. S., Bot, A. I., Rossi, J. M., Lam, N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.004 · Cited by 284 · see citing works
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020) · Blood · doi:10.1182/blood.2020005278 · Cited by 274 · see citing works
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2016) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 263 · see citing works
Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., Gu, C., Zhang, S., Chen, L., Cheng, J., et al. (2019) · Blood · doi:10.1182/blood.2019000017 · Cited by 263 · see citing works
Wang, Y., Zhang, W.-Y., Han, Q.-W., Liu, Y., Dai, H.-R., Guo, Y.-L., Bo, J., Fan, H., Zhang, Y., Zhang, Y.-J., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.10.002 · Cited by 188 · see citing works
CD30 in normal and neoplastic cells.
Chiarle, R., Podda, A., Prolla, G., Gong, J., Thorbecke, G., & Inghirami, G. (1999) · Clinical Immunology · doi:10.1006/clim.1998.4636 · Cited by 183
Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
Ho, W., Blattman, J. N., Dossett, M. L., Yee, C., & Greenberg, P. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00113-2 · Cited by 157 · cited 1× · see citing works
“When encountered with tumors, they can rapidly generate specific tumor-targeted T cells, which may exert both immediate and long-term effects [7, 9, 10].”
BackgroundCao, Y., Lu, W., Sun, R., Jin, X. K., Cheng, L., He, X., Wang, L., Yuan, T., Lyu, C., & Zhao, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00767 · Cited by 152 · see citing works
Neste, E. V. D., Schmitz, N., Mounier, N., Gill, D., Linch, D., Trněný, M., Bouadballah, R., Radford, J., Bargetzi, M., Ribrag, V., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.213 · Cited by 139 · see citing works
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M., & Darcy, P. (2013) · Oncoimmunology · doi:10.4161/onci.26286 · Cited by 139 · see citing works
Zhang, W.-Y., Wang, Y., Guo, Y.-L., Dai, H.-R., Yang, Q.-M., Zhang, Y.-J., Zhang, Y., Chen, M.-X., Wang, C.-M., Feng, K., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.2 · Cited by 134 · see citing works
Lohri, A., Barnett, M., Fairey, R., O'Reilly, S., Phillips, G., Reece, D., Voss, N., & Connors, J. (1991) · Blood · doi:10.1182/blood.v77.10.2292.bloodjournal77102292 · Cited by 121
Zhang, Y.-J., Wang, Y., Liu, Y., Tong, C., Wang, C.-M., Guo, Y.-L., Ti, D.-D., Yang, Q.-M., Qiao, S., Wu, Z.-Q., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01345-8 · Cited by 97 · see citing works
Ying, Z., Yang, H.-Y., Guo, Y., Li, W.-Y., Zou, D., Zhou, D.-B., Wang, Z., Zhang, M.-Z., Wu, J.-Q., Liu, H., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3686 · Cited by 97 · see citing works
Qu, C.-J., Ping, N., Kang, L.-Q., Liu, H.-L., Qin, S.-B., Wu, Q., Chen, X.-C., Zhou, M., Xia, F., Ye, A., et al. (2020) · Journal of immunotherapy · doi:10.1097/cji.0000000000000284 · Cited by 87
Wei, G., Zhang, Y., Zhao, H., Wang, Y., Liu, Y., Liang, B., Wang, X., Xu, H., Cui, J., Wu, W., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0675 · Cited by 73 · see citing works
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
Wang, D., Zeng, C., Xu, B., Xu, J., Wang, J., Jiang, L., Wang, Q., Li, C., Wang, N., Huang, L., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0274-9 · Cited by 60 · see citing works
Elstrom, R., Martin, P., Ostrow, K., Barrientos, J., Chadburn, A., Furman, R., Ruan, J., Shore, T., Schuster, M., Cerchietti, L., et al. (2010) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.3816/clml.2010.n.030 · Cited by 59 · see citing works
Zeng, C., Cheng, J.-L., Li, T.-J., Huang, J., Li, C.-R., Jiang, L.-J., Wang, J., Chen, L.-T., Mao, X., Zhu, L., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.008 · Cited by 38 · see citing works
Zhang, W.-Y., Liu, Y., Wang, Y., Wang, C.-M., Yang, Q.-M., Zhu, H.-L., & Han, W.-D. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.54 · Cited by 23
Ying, Z., Xie, Y., Zheng, W., Liu, W.-P., Lin, N., Tu, M., Wang, X.-P., Ping, L.-Y., Deng, L., Zhang, C., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01888-z · Cited by 7
Grignano, E., Laurent, J., Deau, B., Burroni, B., Bouscary, D., & Kirova, Y. (2018) · European Journal of Haematology · doi:10.1111/ejh.13080 · Cited by 7
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [17]Xiao X Jiang YY Cao YQ Li Q Jin X Meng JX Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma Zhonghua Xue Ye Xue Za Zhi 2019 40 4 276 280 31104437 PMC7343005
Cited by
Sorted by citations
Broadening the horizon: potential applications of CAR-T cells beyond current indications
Karsten, H., Matrisch, L., Cichutek, S., Fiedler, W., Alsdorf, W. H., & Block, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285406 · Cited by 15 · see citing works
Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives
Akunne, O. Z., Anulugwo, O. E., & Azu, M. G. (2024) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_24_2024 · Cited by 7 · see citing works
Tavakoli, S., Samareh-Salavatipour, M., Mardi, A., Salehi-Shadkami, H., Vaezi, M., Barkhordar, M., & Ahmadvand, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-02489-0 · Cited by 3
“So, the common therapeutic approaches are often limited by substantial relapse rates and non-relapse mortality due to treatment-associated toxicity and immune complications [3–5].”
Lin, X., Liu, J., Chen, J., Tang, J., Huang, Z., Wang, Y., & Shi, S. (2026) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100850 · Cited by 1 · see citing works
- Authors
- Che, Y., & Sun, X.
- Affiliations
- Dalian Medical University (CN)
- Corresponding author
- Sun, Xiuhua
- Venue
- Clinical and Translational Oncology
- Published
- 2023-04-16
- Volume
- 25
- Issue
- 10
- Pages
- 2793-2800
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- PMC
- PMC10462491
- OpenAlex
- W4365998117
- Cited by
- 4
- References
- 44
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1
- FWCI
- 0.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Clinical & Translational Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, lymphoma, relapsed/refractory lymphoma, Hodgkin's disease, non-Hodgkin lymphoma, combination therapy, clinical trials, China
- MeSH terms
- Hodgkin Disease, Humans, Lymphoma, Lymphoma, Non-Hodgkin, Prognosis, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
